EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessment of coronavirus disease 2019 mRNA vaccine response in kidney transplant recipients

Mohamad M Alkadi iD, Essa A Abuhelaiqa, Rasha M Abdul Rahman, Ali B Mahgoub, Abdullah I Hamad, Peter V Coyle iD, Zahir M Tag iD, Laith J Abu Raddad, Hassan A Al-Malki

PLOS One · 04.11.2026 · 21 (11) · e0359640

DOI: 10.1371/journal.pone.0359640 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 04.11.2026. Verfasst von Mohamad M Alkadi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Nephrology, Hamad Medical Corporation, Doha, Qatar. Hauptthemen laut MEDLINE: Kidney Transplantation, COVID-19 Vaccines, COVID-19, SARS-CoV-2. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kidney transplant recipients are vulnerable to developing severe coronavirus disease 2019 (COVID-19) infection. Although mRNA vaccines have significantly improved outcomes, seropositivity rates remain variable in immunosuppressed patients. This study aimed to evaluate the antibody response to COVID-19 mRNA vaccines, identify factors affecting immunogenicity, and examine the association between antibody titers and subsequent SARS-CoV-2 infection and COVID-19-related hospitalization among kidney transplant recipients. We retrospectively studied 372 adult kidney transplant recipients who received two doses of COVID-19 mRNA vaccine after transplantation and had anti-SARS‑CoV‑2 spike protein receptor-binding domain antibodies measured ≥ 14 days after the second dose and prior to receiving a third dose. We categorized patients based on previous COVID-19 infection, post-vaccination antibody status (seropositive or seronegative), and antibody titers (low or high). Factors associated with poor vaccine response (seronegativity) and with high antibody titers (antibody titer ≥ 121 U/mL) were determined using multivariable regression models. The proportion of patients with subsequent COVID-19 infection was higher in the seronegative group than in the seropositive or previous infection groups (36% vs. 26% vs. 13%, respectively; P = 0.02). Multivariable regression analysis revealed higher odds of poor response to the mRNA vaccine among patients aged > 52 years compared with those aged ≤ 52 years (aOR = 1.94; 95% CI: 1.12–3.36; P = 0.018). Lower odds were observed among male patients (aOR = 0.43; 95% CI: 0.24–0.77; P = 0.004) and those taking azathioprine (aOR = 0.26; 95% CI: 0.07–0.91; P = 0.035). The proportion of patients with subsequent COVID-19 was also higher in the low-antibody group than in the high-antibody group (33% vs. 20%; P = 0.02). Multivariable logistic regression analysis showed lower odds of high SARS-CoV-2 antibody titers among patients aged > 51 years compared with those aged ≤ 51 years (aOR = 0.43; 95% CI: 0.24–0.75; P = 0.003). Higher odds were observed among those of African race (aOR = 2.82; 95% CI: 1.11–7.16; P = 0.03) and South Asian race (aOR = 2.27; 95% CI: 1.08–4.75; P = 0.03) compared with Middle Eastern recipients. Understanding the immunologic response to the SARS-CoV-2 vaccine in kidney transplant recipients is essential for preventing potentially life-threatening infection. Furthermore, identifying transplant recipients with a low vaccine-induced antibody response may help guide the development of individualized immunization strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationCOVID-19 VaccinesCOVID-19SARS-CoV-2HumansMaleMiddle AgedFemaleRetrospective StudiesAntibodies, ViralAdultAgedTransplant Recipients

Substanzen

COVID-19 VaccinesAntibodies, Viral

Autor:innen und Institutionen

  • Department of Medicine, Division of Nephrology, Hamad Medical Corporation, Doha, Qatar.
  • Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar.
  • Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.

ORCID-Profile: Mohamad M Alkadi, Peter V Coyle, Zahir M Tag

Zitieren

APA

Alkadi, M. M., Abuhelaiqa, E. A., Abdul Rahman, R. M., Mahgoub, A. B., Hamad, A. I., Coyle, P. V., Tag, Z. M., Abu Raddad, L. J., & Al-Malki, H. A. (2026). Assessment of coronavirus disease 2019 mRNA vaccine response in kidney transplant recipients. PLOS One, 21(11), e0359640. https://doi.org/10.1371/journal.pone.0359640

Vancouver

Alkadi MM, Abuhelaiqa EA, Abdul Rahman RM, Mahgoub AB, Hamad AI, Coyle PV, et al. Assessment of coronavirus disease 2019 mRNA vaccine response in kidney transplant recipients. PLOS One. 2026;21(11):e0359640. doi:10.1371/journal.pone.0359640

BibTeX
@article{Alkadi2026,
  author = {Alkadi, Mohamad M and Abuhelaiqa, Essa A and Abdul Rahman, Rasha M and Mahgoub, Ali B and Hamad, Abdullah I and Coyle, Peter V and Tag, Zahir M and Abu Raddad, Laith J and Al-Malki, Hassan A},
  title = {Assessment of coronavirus disease 2019 mRNA vaccine response in kidney transplant recipients},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {11},
  pages = {e0359640},
  doi = {10.1371/journal.pone.0359640}
}
Kostenlos starten →